Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria

There are limited treatment options for unresectable recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Vascular endothelial growth factor is of significant interest for targeted therapy in R/M HNSCC because of its central role in tumorigenesis and immunosuppression. Axitinib is a potent inhibitor of vascular endothelial growth factor receptor (VEGFR) 1 , VEGFR2, VEGFR3, platelet‐derived growth factor receptor, as well as c‐kit and offers such an approach.

[1]  A. Hérault,et al.  Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia , 2020, Cancer Immunology Research.

[2]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[3]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[4]  Katherine E Henson,et al.  Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England , 2019, JAMA dermatology.

[5]  E. Schmidt,et al.  A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck. , 2018 .

[6]  C. Reddy,et al.  A multi‐institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck , 2017, Cancer.

[7]  A. Hakimi,et al.  The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.

[8]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[9]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[10]  K. Malloy,et al.  A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer , 2015, Investigational New Drugs.

[11]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[12]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[13]  E. Yang,et al.  Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen , 2013, Nature Immunology.

[14]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[15]  E. Tartour,et al.  VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.

[16]  A. Maity,et al.  Molecular Neuroscience Review Article , 2011 .

[17]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[19]  C. Bokemeyer,et al.  Platinum-based chemotherapy plus cetuximab in head and neck cancer. , 2008, The New England journal of medicine.

[20]  L. Ohno-Machado,et al.  Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications , 2008, Laboratory Investigation.

[21]  A. Schueler,et al.  Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Hong,et al.  Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Reichert,et al.  Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[25]  J. Wang-Rodriguez,et al.  Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. , 2005, American journal of clinical pathology.

[26]  J. Ioannidis,et al.  Prognostic Significance of Vascular Endothelial Growth Factor Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis , 2005, Clinical Cancer Research.

[27]  Benjamin D. Smith,et al.  Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  K. Hörmann,et al.  The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. , 2009, International journal of oncology.